Business Wire

Verimatrix and Velocix Team Up to Fight CDN Piracy

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced a strategic collaboration with Velocix, the market’s premier carrier-grade CDN software provider, to help streaming providers combat piracy, boost paid video subscriptions, and cut CDN costs. This joint initiative provides streaming providers with the means to detect, deny, and prevent unsanctioned usage of CDN capacity by third parties.

CDN leeching, where unauthorized users consume content directly from the network without paying for it, is a critical and costly challenge for video service providers. Verimatrix Streamkeeper™ Counterspy protects the client side, ensuring only legitimate users can access content, by providing string app authentication, protecting content keys, and safeguarding the token exchange. Velocix’s Carrier-Grade CDN and Video Analytics Platform bring powerful server-side features, including advanced tokenization schemes, rate throttling, token revocation, and AI-powered anomaly detection. Together, the companies combined strengths across the delivery chain provide a means to stop stream piracy, safeguard premium content, and reduce delivery costs. Operators can also grow video subscriptions by enforcing paid relationships and improving the experience for legitimate subscribers by unlocking pirated bandwidth on the CDN for paid users. CDN demands can be reduced by 30% or more during peak usage periods thanks to the elimination of illicit traffic.

“Collaborating with Velocix was a logical step for Verimatrix, as we have complementary technology and share a common goal of protecting streaming provider’s bottom line from the scourge of stream piracy,” said Carlo Stramaglia, head of Anti-Piracy Business at Verimatrix. “Streamkeeper Counterspy was designed to work hand-in-hand with CDNs, and Velocix is the ideal partner to showcase how we can turn piracy protection into a direct cost-saving and revenue-generating advantage for our customers and theirs.”

“CDN leeching is a critical concern for the streaming industry because the negative impacts to video businesses are big, real, and happening right now,” said Marco Rico, Head of Products at Velocix. “Our alliance with Verimatrix, enables us to combine our considerable experience to offer operators a clear path to combat stream theft to both reduce costs and drive higher returns, enabling them to run better, more profitable video businesses.”

This collaboration signals a major opportunity for broadcasters, pay-TV operators, and streaming providers seeking a holistic approach to tackling piracy and ensuring optimal business performance.

To learn more, watch the joint webinar, “Stop the Steal: Inside CDN Leeching & Piracy” on demand here or meet with the teams in person at IBC 2025, RAI Amsterdam, from September 12th-15th: Schedule a meeting with Verimatrix (Hall 1 – BS.20), or request a meeting with Velocix (Hall 5 – C.75).

About Velocix
Velocix is the world’s leading provider of carrier-grade video streaming, control plane, and analytics technology, powering exceptional entertainment experiences for the world’s largest operators. Its hybrid-cloud software solutions scale to support billions of viewing sessions every year, enabling operators to maximize efficiency, security, and monetization of their video services. Learn more at www.velocix.com.

About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909231415/en/

Contacts

Velocix Media Contact:
Jane Allan
jane.allan@velocix.com

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

SEITOSEI.ACTIFIN
Michael Scholze
michael.scholze@seitosei-actifin.com

Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press Release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGA Company Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press Release

AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV Specialty, Risico, Collegiate, ANV Nordic, Arc Legal, Qualis, and Abacus. These businesses provide diverse risk and insurance coverages including cyber excess and surplus (E&S), directors and

Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press Release

Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press Release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye